Print page

Home » Articles » Therapeutic Dose

Where Is the Outrage and the Shame?

Do Americans really care more about see-through yoga pants than defective pills and implants?


By Emil Ciurczak, Contributing Editor

This week I watched a report on TV where there was massive Twitter response to the fact that several lots of exercise leotards/yoga pants, distributed by LuluLemon, were see-through when worn. Tens of thousands of outraged Tweets and Facebook postings were sent around the world. 

The top tax rate for millionaires rises from 33 to 35% and tens of thousands of protesters (none making that much in income) protest in televised events.

Large numbers of birth control tablets were mislabeled, causing some pregnancies, and….cue the crickets. What? No one upset? Apparently, inconsequential (social) instances are either more important or more easily understood, so these incidents get more press than real health risks.

When Ranbaxy Laboratories stopped production of its generic version of Lipitor while it “investigates the issue of contamination in certain lots” (at least 14 lots were recalled) due to glass particles in their tablets. I only read about it in trade journals … the major news media seem to have missed it. Our friends at Johnson & Johnson have been making the news over the past few years as well.

For instance, a New Jersey jury has ordered J&J to pay punitive damages of $7.76 million to a former nurse who blames its vaginal mesh implant for years of severe pain despite 18 unsuccessful repair surgeries.1 A spokesman for the plaintiff’s lawyers said the award adds to $3.35 million in compensatory damages awarded by the state Superior Court jury earlier this week. It’s the first verdict in about 4,000 lawsuits filed against the company, based in New Brunswick, N.J. (J&J says the decision isn’t supported by the evidence and the company plans to appeal). 

In the latest in a string of J&J recalls, the giant’s McNeil unit removed three types of K-Y Jelly from pharmacy and grocery store shelves, and recalled shipments delivered to wholesalers, at the end of January. The company has quietly recalled some of its popular products in order to avert potentially expensive new regulatory reviews. 

In addition, “A court jury in Los Angeles on Friday awarded $8.3 million in damages to man who said he was injured by J&J’s all-metal hip implants, which the jury found were designed defectively.”2 The verdict ended the first case to go to trial of about 10,750 product-liability lawsuits against J&J’s DePuy unit, which manufactured the devices. The jury declined to award punitive damages, but costs will add up. (I must have missed the newspapers the day this was covered.) In addition, in 2010, J&J recalled hip replacements implanted in about 93,000 people because an excessive number needed a second hip-replacement procedure. The recall sparked lawsuits, with some patients alleging that potentially toxic metal particles wore away from their all-metal hip parts, entering patients’ bloodstreams. J&J has since taken hundreds of millions of dollars in charges to cover medical and litigation costs related to the recalled products.

Lost product sales and factory upgrades have cost J&J well over $1 billion. In addition, J& J’s manufacturing operations remain under increased scrutiny from the FDA. So, what “meaningful” actions were taken against those responsible for so many errors? Well, J&J has lowered planned bonuses by 10% for new CEO Alex Gorsky and other top executives. The health products maker cited a “mix of short-term successes and disappointments” last year, including its failure to get many of its recalled nonprescription medicines back into stores as quickly as promised. Wow! Almost a death penalty.

Still, Mr. Gorsky received total compensation worth $8.93 million, up approximately 62 percent from the $5.52 million total he received in 2011 and promoted from vice chairman to CEO last April. 

A brief review of the news brings a daily dose of drug company problems. Problems of quality, in fact, that are not “accidents,” but due to lack of quality systems enforcement. Unfortunately, major corporations (not to just single out J&J) are not getting the press needed for reform (court fines are seen as the cost of doing business). Apparently, the FDA does not have the support (financially or philosophically) of Congress to attack the problems more aggressively. And, worst of all, the public doesn’t have the same passion over life-threatening problems that they seem to have over see-through yoga pants!

Published in the May 2013 issue of Pharmaceutical Manufacturing magazine

References

 

1.     “LuluLemon pants problem,” Today Show, 3/19/2013

2.     USFDA announcement

3.     “Jury Adds $7.8M in J&J Punitive Damages”, Thu, 02/28/2013 - 12:18pm, The Associated Press

4.     “Calif. Jury Awards $8.3 Million in Lawsuit Vs. J&J Over Faulty Hip Implants”,Published March 08, 2013, Dow Jones Newswires

5.     “J&J Lowers Exec Bonuses, Citing 'Disappointments'”, Wed, 03/13/2013, L. A. JOHNSON - AP Business Writer - Associated Press 


More From This Voice:

Where Is the Outrage and the Shame?
05/13/2013
Do Americans really care more about see-through yoga pants than defective pills and implants?

PittCon Observations from the Floor
04/30/2013
The trend to smaller and smaller instruments has become a goal for most companies, and miniature spectrometers had a big presence

Hiding the Costs of Outsourcing
03/20/2013
Be sure to weigh all of the pros and cons as well as ROI before making the decision to outsource

Therapeutic Dose: How I was Shanghaied (and Surprised)
12/18/2012
Watch out. Asian pharma professionals are serious about learning how to do PAT and QbD

Therapeutic Dose: Enemies Within
11/29/2012
FDA’s hard pressed to inspect offshore facilities; now it also faces compounders and other domestic challenges.

Therapeutic Dose: Who's on First?
05/23/2012
When it comes to QbD, we keep using that word, but does it mean what we think it means?

Therapeutic Dose: Reforesting Innovation
04/11/2012
Trade show consolidation can be a good thing, at least when it gives smaller innovator companies room to grow.

Therapeutic Dose: A One-Trick Pony Won’t Carry Continuous Processing
02/14/2012
Sometimes, analytical methods, including NIR, just aren’t enough.

Therapeutic Dose: Protecting Pharma's Supply Chain
02/14/2012
Until we can examine every supplier of excipient and API, we’ll need to do our own detective work, but that will help us with Quality by Design.

Therapeutic Dose: Sampling: Good News, Bad News
01/03/2012
Changing from the status quo to meaningful testing will satisfy both FDA and ASTM.

Therapeutic Dose: Fractal Pharma
11/15/2011
When the whole so closely resembles the individual parts, where is the big picture, or the path to continuous improvement?

Therapeutic Dose: Time to Extrapolate QbD?
10/04/2011
Preformulation, formulation and stability testing are all embracing QbD.

Therapeutic Dose: Problems in Pharma? Time to Examine the Rules
09/28/2011
Enforcing existing laws is a start.

Therapeutic Dose: Facilius per Partes in Cognitionem Totius Adducimur
07/20/2011
We are more easily led part by part to an understanding of the whole. –Seneca

Therapeutic Dose: The Greening of Pharma
06/14/2011
Is the greening of pharma merely moss on a stagnant stone?

Therapeutic Dose: Will PAT Have an Easier Path in Biopharma?
05/16/2011
The scientists who design biopharma products tend to be the same as those who analyze them.

Therapeutic Dose: Greening the Pharma Lab
04/11/2011
Reducing environmental impact may not have been vendors’ primary goal, but it has been a welcome result, allowing dramatic cost savings.

Therapeutic Dose: Even da Vinci Needed Some Help
03/15/2011
A lot of the “walking” we’ve done should now allow us to run, or fly.

Therapeutic Dose: Good Enough is Not Good Enough
02/07/2011
As mom used to say on my report card: you could do better.

Therapeutic Dose: It Seemed Like a Good Idea at the Time
01/12/2011
Saving money through outsourcing is really starting to cost us.

Therapeutic Dose: Sympathizing with da Vinci
12/06/2010
Like Leonardo, we’ve got great technologies, just not the infrastructure and support for them.

Therapeutic Dose: In Praise of Spinoffs
10/06/2010
Sputnik and Telecom have transformed analytics forever

Therapeutic Dose: Houses Built on Sand
09/10/2010
Our foundations for Quality by Design are of poor quality, yet industry and FDA continue to let things slide.

Therapeutic Dose: Throwing out the Bathwater, the Baby, the Tub . . .
08/03/2010
Big manufacturers have forgotten why they grew big in the first place, to the severe detriment of their PAT and QbD programs, says Contributing Editor Emil Ciurczak.

Therapeutic Dose: Lipstick on a Pig
06/09/2010
No matter how we dress it up, PAT, "Product Assurance" Technology is still about control.

Therapeutic Dose: Life-Cycle Management: A Veritable Hydra
05/12/2010
Should improved process control or safety measures extend a product's patent exclusivity?

Therapeutic Dose: Qbd: A Pinch of This and a Dash of That
04/13/2010
Why can't QbD be, literally, as easy as pie?

Therapeutic Dose: One Lot a Week?
02/16/2010
With improvements in instrumentation and analytics, continuous pharmaceutical processing has entered the realm of the possible.

Therapeutic Dose: Residual Solvents and a Trace of Cooperation
02/02/2010
The new guidelines are evidence of multinational law enforcement at its best.

Therapeutic Dose: New Year, New Hope
12/16/2009
Pharma may not be adopting PAT and QbD wholesale, but smaller, more powerful hardware offers a glimmer of hope.

Therapeutic Dose: When You Have Fired the Crew, Who Will Row the Boat?
10/09/2009
Without a full complement of scientists, where will the spinoffs and innovative side benefits come from?

Therapeutic Dose: Track Laying and Lessons from Amtrak
09/01/2009
With PAT and QbD, we built the high-speed trains before we laid down the rails—can we build the infrastructure?

Therapeutic Dose: Exploding Silos in Pharma Production
07/22/2009
Think silos were invented here? Guess again. They’re universal.

Therapeutic Dose: Beam Me Some Data, Scotty!
06/10/2009
The satellites are up there; why not use them for anticounterfeiting?

Therapeutic Dose: Troubles with Outsourcing?
06/02/2009
Maybe you’re just too “far out” and should look closer to home.

Therapeutic Dose: Low Attendance at Trade Shows? Blame PAT
04/09/2009
We just don't get together like we used to. Is this okay?

Therapeutic Dose: Want More Scientists? Show Them the Money
03/03/2009
"Doing more with less" has made boiling frogs out of us all, as we accept limitations on time and income. Is this any way to attract young people to science and engineering?

Therapeutic Dose: QbD and PAT: What’s In It for the Little Guy?
02/09/2009
Why should mom-and-pop manufacturers invest in process improvement when the risk-reward ratio is against it?

Therapeutic Dose: Fighting Fair
01/15/2009
Rather than real-time product release, pharma PAT efforts should focus on modernizing API and raw material analytical methods.

Therapeutic Dose: Nutraceuticals: Another Insurmountable Opportunity for FDA
12/30/2008
Natural doesn’t necessarily mean safe.

Safe Materials from Overseas: What Tools Does FDA Have?
10/23/2008
Material safety is an industry issue, not an Agency issue.

Therapeutic Dose: The Man Behind the Curtain
09/23/2008
Adopting PAT and QbD can be done, with legislative encouragement

Therapeutic Dose: Be Careful What You Wish For
08/18/2008
Decisions on product liability and labeling may make it harder for consumers to sue, but could decrease industry profits and make clinical trials longer and more litigious than they already are.

Therapeutic Dose: Only Placebos Are Risk-Free (Unless You’re Lactose Intolerant)
06/23/2008
Drug safety is a multifaceted question. Let’s be reasonable before going Chicken Little on the industry.

Therapeutic Dose: Conservation of Natural Resources
05/19/2008
Like open-pit mining, too great a focus on reduced labor costs leaves toxic tailings.

Therapeutic Dose: Extending QbD to Stability Testing
04/08/2008
The concept of a process signature can easily be extended to stability testing.

Therapeutic Dose: Ready, Aim, Aim, Aim…
02/28/2008
Risk management in the 21st century: We have the tools, but do we have the will?

Therapeutic Dose: When the Truth Is Found to Be Lies [1]
02/06/2008
Expecting the drug industry to police itself is unrealistic; granting FDA more power and funding to supervise clinical trials may be the answer

Therapeutic Dose: How Do You Test for Creativity?
01/10/2008
Hiring people who already know their jobs and will faithfully do them over and over will not get us to a working model of QbD.

Therapeutic Dose: The Perfect Storm
10/10/2007
(Financial pressures + regulatory changes) = new manufacturing paradigm (- breadth of experience + narrow focus) = problems achieving Quality by Design.

Therapeutic Dose: How Can I Miss You If You Won't Go Away?
09/28/2007
Our 'humble narrator' offers a counterpoint to last month's column on oursourcing; here, he makes a case for telecommuting.

Therapeutic Dose: Why Waste Time and Money on PAT? A Modest Proposal
08/29/2007
The globalization of business and the labor market provides a tempting trap for pharma companies.

Therapeutic Dose: 'Til Death do us Part... But First, Here's the Pre-Nuptial Agreement
07/17/2007
The CAPA is still necessary, but it needs to morph into something new under the QbD and PAT manufacturing examples.

Therapeutic Dose: You Can’t Cheat an Honest Man [1]
05/22/2007
. . . or fabrum esse suae quemque fortunae [2] (translation: “Each man the architect of his own fate”)

Therapeutic Dose: Life is Just a Bowl of Entropy
04/19/2007
As the saying goes, “If the only tool you have is a hammer, all problems resemble nails.” As a physical chemist, I think I can explain everything in terms of thermodynamics. I have yet to be proven wrong.

Therapeutic Dose: The Times They Are A-Changin'
03/28/2007
Until and unless the academic community responds with 21st century curricula, we will have to work with the graduates we have, not the graduates we would like to have.

Therapeutic Dose: Wishing Won’t Make It So
03/05/2007
A new generation of scientists and engineers will be needed to make PAT and QbD a reality, both within companies and regulatory agencies. Training will be the key.

Therapeutic Dose: The Importance of Design Qualification
12/26/2006
The DQ is a critical, yet often overlooked part of the process of developing and validating any new pharmaceutical PAT process. It is a strategically important time, where process engineers, material scientists and physical chemists can get together to develop meaningful materials characterization standards.

PAT in Perspective: Safe? Yes. Effective? Not So Much.
12/05/2006
PAT expert Emil Ciurczak points out that a repository of methods and standard practices, terms, units, etc. is critical to understanding (and thus controlling) the process of producing good, predictable, and reproducible solid dosage forms.

Therapeutic Dose: Buying Sneakers Isn’t Running the Marathon
10/30/2006
It’s time to emphasize the “P,” and de-emphasize the “A” and the “T” in PAT, says our intrepid columnist.

Therapeutic Dose: Avoiding "Cool Hand Luke" Syndrome: Part II
09/26/2006
At a time when the amount of available data is increasing exponentially, why are we isolating ourselves from our brethren and the larger scientific community?

Therapeutic Dose: Getting to Know Used
06/21/2006
New equipment isn’t always an option, and used is losing its stigma.

Therapeutic Dose: Courting Biotech
05/18/2006
Biotech may be big, but is there enough to go around?

Therapeutic Dose: For a Pandemic, Call Out the Guard
04/17/2006
A "national guard" for vaccine distribution is just one big idea to boost flu preparedness.

Is Your Diversity Diverse Enough?
03/07/2006
Initiatives that focus on women and minorities may miss the big picture.

Therapeutic Dose: Pharma Bloggers: Unite and Write!
02/16/2006
You have nothing to lose (but your job, if you’re not careful).

  • Featured White Papers